Skin biopsy specimens of three lesions on her back were consistent with cutaneous T-cell lymphoma (CTCL). On physical examination, she had erythematous patches and plaques with ill-defined borders ...

Beckman Research Institute of The City of Hope, Duarte, CA.

Investing.com -- Shares of Soligenix (NASDAQ: SNGX) climbed 2.9% following the company’s announcement of promising results for its skin cancer treatment, HyBryteTM, in treating cutaneous T-cell ...

Watch here: Soligenix $SNGX HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding ...

Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company focused on rare diseases, is featured in a new Benzinga video detailing clinical pr ...

The US regulator has cleared Lymphir (denileukin diftitox) for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL ... by debilitating skin lesions and severe itching.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” said ...

Among some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, treatment with the bispecific antibody odronextamab has been associated ...

NICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL) in adults who did not respond to two or more previous treatments. The drug will be ...

15, 2025 — Growing cells in the laboratory ... prolonged sitting impairs forearm cutaneous vasodilation function. They also showed that alternating local skin ... Discovery Reveals Protein ...

Hi, everyone, and welcome to the next episode of our CEO Fireside Chats. My name is David Bautz and I'm a senior biotechnology analyst here at Zacks Small Cap Research. Joining me today is Chris ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...